|Bid||0.00 x 0|
|Ask||957.80 x 0|
|Day's range||954.50 - 965.80|
|52-week range||356.75 - 965.80|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||46.97|
|Earnings date||06-Aug-2019 - 10-Aug-2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
New Delhi, Jun 23 (PTI) Drug major Cipla on Wednesday said it has received final approval from the US health regulator for Arformoterol Tartrate Inhalation Solution, used to treat conditions like chronic bronchitis and emphysema, in the US market.
New Delhi, Jun 15 (PTI) Drug firm Cipla on Tuesday said its step-down associate firm Avenue Therapeutics Inc has received a second complete response letter (CRL) from the US health regulator for its new drug application for intravenous tramadol.
New Delhi, June 1 (PTI) Following are the top business stories at 1940 hours: DEL21 BIZ-MOODYS LD-INDIA-GDP Indian economy to grow 9.3 pc in FY22, 2nd COVID wave raises risks to credit profile: Moody's New Delhi: Indian economy would rebound in the current fiscal ending March 2022 and clock a growth of 9.3 per cent, but a severe second COVID wave has increased risks to India's credit profile and rated entities, Moody's Investors Service said on Tuesday.